Akero Therapeutics

Akero Therapeutics company information, Employees & Contact Information

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Special Advisory: Job applicants should be aware of online recruitment scams, including fraudulent interviews and fake job offers. Akero does not conduct interviews through text messages or messaging apps, will never request money from applicants, and communicates only via emails ending with "@akerotx.com." Please verify that any communication claiming to be from Akero comes from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission.

Company Details

Employees
69
Founded
-
Address
601 Gateway Blvd,
Email
in****@****otx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Akero Therapeutics employee's phone or email?

Akero Therapeutics Questions

News

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion - Yahoo Finance

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Yahoo Finance

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

Clinical-Stage Biotech Akero Therapeutics to Showcase Metabolic Disease Pipeline at Major Healthcare Conference - Stock Titan

Clinical-Stage Biotech Akero Therapeutics to Showcase Metabolic Disease Pipeline at Major Healthcare Conference Stock Titan

Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases - PR Newswire

Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases PR Newswire

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH - GlobeNewswire

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH GlobeNewswire

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases - PR Newswire

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases PR Newswire

Akero Therapeutics Announces Initiation of Phase 3 - GlobeNewswire

Akero Therapeutics Announces Initiation of Phase 3 GlobeNewswire

Akero Therapeutics Reports Encouraging 36-Week Analysis of - GlobeNewswire

Akero Therapeutics Reports Encouraging 36-Week Analysis of GlobeNewswire

Top Akero Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant